Radioimmunotherapy using 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Clinical Cancer Research

• Publication date

  1999-10-01

• Fields of study

  Medicine

• Identifiers
  PMID 10541377
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

  1998cited by this paper
• The use of cyclosporin-A in the treatment of virus-associated hemophagocytic syndrome in adults.

  1997cited by this paper
• Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22

  1997cited by this paper
• Outcome of twin gestations complicated by a single anomalous fetus

  1996cited by this paper
• Radioimmunotherapy of relapsed B-cell lymphoma with yttrium 90 anti-idiotype monoclonal antibodies.

  1996cited by this paper
• Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma.

  1996cited by this paper
• Hyperresponsive B Cells in CD22-Deficient Mice

  1996cited by this paper
• Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma.

  1996influential reference
• Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody.

  1995cited by this paper
• Radioimmunotherapy of the Non-Hodgkin's Lymphomas.

  1995cited by this paper
• Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides.

  1995cited by this paper
• Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

  1995cited by this paper
• Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group.

  1994cited by this paper
• Internalization and intracellular processing of an anti B‐cell lymphoma monoclonal antibody, ll2

  1994cited by this paper
• Molecular mechanisms regulating CD19, CD20 and CD22 gene expression.

  1994cited by this paper
• Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma

  1994cited by this paper
• A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.

  1994cited by this paper
• A chimeric mouse/human anti-IL-2 receptor antibody with enhanced biological activities.

  1992cited by this paper
• Evaluation of a remote radioiodination system for radioimmunotherapy.

  1990cited by this paper
• Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle.

  1990cited by this paper
• Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies.

  1989cited by this paper
• Long-term results of low dose total body irradiation for advanced non-Hodgkin lymphoma.

  1987cited by this paper
• Results of total body irradiation in the treatment of advanced non‐Hodgkin's lymphomas

  1979cited by this paper

• Predictive value of pre-treatment FDG PET in patients with non-Hodgkin lymphoma treated with radioimmunotherapy: a systematic review

  2019cites this paper
• Radioimmunotherapy as the first line of treatment in non-Hodgkin lymphoma.

  2018cites this paper
• Radioimmunotherapy in non-Hodgkin lymphoma: Prediction and assessment of response.

  2016cites this paper
• Monoclonal Antibodies in Paediatric Acute Lymphoblastic Leukemia

  2011cites this paper
• New Agents for the Treatment of Acute Lymphblastic Leukemia

  2011cites this paper
• Radiobiology: Concepts and Basic Principles

  2010cites this paper
• Radiolabeled immunotherapy in non-Hodgkin's lymphoma treatment: the next step

  2009cites this paper
• Evaluation of quantitative planar 90Y bremsstrahlung whole-body imaging

  2009cites this paper
• Novel antibodies in the treatment of non-Hodgkin's lymphoma.

  2009cites this paper
• Diagnostic imaging prior to 90Y-ibritumomab tiuxetan (Zevalin) treatment in follicular non-Hodgkin's lymphoma.

  2008cites this paper
• Newer monoclonal antibodies for hematological malignancies.

  2008cites this paper
• Does health economics have an impact on non-Hodgkin's lymphoma patients' options?

  2008cites this paper
• Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies

  2007cites this paper
• Internal dosimetry as a tool for radiation protection of the patient in nuclear medicine

  2007cites this paper
• Current results and future applications of radioimmunotherapy management of non-Hodgkin's lymphoma

  2006cites this paper
• Identification of Candidate Target Antigens for Antibody-Based Immunotherapy in Childhood B-Cell Precursor ALL

  2006cites this paper
• Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma.

  2006cites this paper
• Radioimmunotherapy of non-Hodgkin's lymphomas.

  2006cites this paper
• Epratuzumab in the therapy of oncological and immunological diseases

  2006cites this paper
• Radioimmunotherapy of non-Hodgkin’s lymphoma: a critical appraisal

  2005cites this paper
• Evaluation of methods for red marrow dosimetry based on patients undergoing radioimmunotherapy

  2005cites this paper
• Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab

  2005cites this paper
• Pharmacokinetic modeling for optimization of radioimmunotherapy – macroscopic and microscopic approach

  2005cites this paper
• Development of humanized antibodies as cancer therapeutics.

  2005cites this paper
• Antibody-guided radiation therapy of cancer

  2005cites this paper
• Treatment of non-Hodgkin's lymphoma (NHL) with radiolabeled antibodies (mAbs).

  2005cites this paper
• Myelosuppressive side-effects of radioimmunotherapy of non-Hodgkin's lymphoma: is there an increased risk?

  2005cites this paper
• Chronic Lymphocytic Leukemia

  2004influential citation
• Epratuzumab, a Humanized Anti-CD22 Antibody, in Aggressive Non-Hodgkin’s Lymphoma

  2004cites this paper
• Potent and Specific Antitumor Efficacy of CMC-544, a CD22-Targeted Immunoconjugate of Calicheamicin, against Systemically Disseminated B-Cell Lymphoma

  2004cites this paper
• Monoclonal antibody therapy in lymphoid leukemias.

  2004cites this paper
• Monoclonal Antibody Therapy in Chronic Lymphocytic Leukemia

  2004cites this paper
• Advancing role of radiolabeled antibodies in the therapy of cancer

  2003cites this paper
• Radioimmunotherapy of non-Hodgkin lymphomas.

  2003cites this paper
• Epratuzumab: targeting B-cell malignancies through CD22.

  2003cites this paper
• Tumour therapy with radionuclides: assessment of progress and problems.

  2003cites this paper
• CD22-directed monoclonal antibody therapy for lymphoma.

  2003cites this paper
• New strategies in radioimmunotherapy for lymphoma

  2003cites this paper
• 3D Absorbed Dose Calculations Based on SPECT: Evaluation for 111-In/90-Y Therapy using Monte Carlo Simulations

  2003cites this paper
• Generation of a highly stable, internalizing anti‐CD22 single‐chain Fv fragment for targeting non‐Hodgkin's lymphoma

  2003cites this paper
• Targeted therapy of cancer with radiolabeled antibodies.

  2002cites this paper
• Development of Radioimmunotherapy for the Treatment of Non-Hodgkin’s Lymphoma

  2002cites this paper
• Ligand-targeted therapeutics in anticancer therapy

  2002cites this paper
• An activity quantification method based on registration of CT and whole-body scintillation camera images, with application to 131I.

  2002cites this paper
• 131I-labelled anti-CD22 MAb (LL2) in patients with B-cell lymphomas failing chemotherapy. Treatment outcome, haematological toxicity and bone marrow absorbed dose estimates.

  2002cites this paper
• Time dependence of the activity concentration ratio of red marrow to blood and implications for red marrow dosimetry

  2002cites this paper
• The role of positron emission tomography in gastrointestinal imaging.

  2002cites this paper
• A 3-dimensional absorbed dose calculation method based on quantitative SPECT for radionuclide therapy: evaluation for (131)I using monte carlo simulation.

  2002cites this paper
• Clinical Applications of Targeted Therapeutics

  2002influential citation
• Radioimmunotherapy of B-cell non-Hodgkin's lymphoma

  2001cites this paper
• RCAS1 as a tumour progression marker: an independent negative prognostic factor in gallbladder cancer

  2001cites this paper
• Registration of emission and transmission whole-body scintillation-camera images.

  2001cites this paper
• Antibody-targeted immunotherapy for treatment of malignancy.

  2001cites this paper
• The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy.

  2001cites this paper
• [Radioimmunotargeting: diagnosis and therapeutic use].

  2000cites this paper
• Red cell transfusion : a practical guide

  1998cites this paper